Lupin`s Generic Ropivacaine Hydrochloride Receives Approval in the U.S.
Enforcement Report - Week of December 13, 2023
Enforcement Report - Week of June 7, 2023
Cali Biosciences Initiates Phase III Studies of CPL-01 (Long-Acting Ropivacaine) to Decrease Post-Operative Pain and Reduce or Eliminate Opioid Use
Enforcement Report - Week of April 5, 2023
Gland's Generic Ropivacaine Hydrochloride Receives Approval in the U.S.
Cali Biosciences Presents Phase IIa Clinical Data on CPL-01, a Long-Acting Ropivacaine
Hikma`s Generic Ropivacaine Hydrochloride Receives Approval In US